NORD writes PhRMA
Executive Summary
National Organization for Rare Disorders criticizes Pharmaceutical Research & Manufacturers of America for ads suggesting that without drug patents research on rare diseases would decline. "The exclusivity provision of the Orphan Drug Act precludes competition for seven years with a higher degree of certainty [than patents], and this has influenced hundreds of companies to invest in orphan drug research and development," NORD says in June 6 letter...